Top Page
Winshine Science Co., Ltd.
(0209)
Winshine Science Co., Ltd. (0209) vs. iShares MSCI Hong Kong ETF (EWH)
Winshine Science Co., Ltd. Business Overview & Revenue Model
Winshine Science Co., Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 473.15M | 515.91M | 523.26M | 849.10M | 724.63M | 364.31M |
| Gross Profit | -1.30M | 12.80M | 39.27M | 97.88M | 37.26M | 18.52M |
| EBITDA | -33.14M | -28.48M | 5.74M | 36.37M | -95.91M | -73.52M |
| Net Income | -84.76M | -73.03M | -28.65M | 8.08M | -136.01M | -95.78M |
Balance Sheet | ||||||
| Total Assets | 322.50M | 352.88M | 414.32M | 340.95M | 550.35M | 484.69M |
| Cash, Cash Equivalents and Short-Term Investments | 34.13M | 55.26M | 119.33M | 49.77M | 66.63M | 57.90M |
| Total Debt | 231.55M | 219.56M | 243.96M | 195.73M | 276.62M | 235.80M |
| Total Liabilities | 497.94M | 493.37M | 495.19M | 430.59M | 649.29M | 446.79M |
| Stockholders Equity | -173.78M | -139.04M | -80.06M | -89.65M | -98.94M | 37.90M |
Cash Flow | ||||||
| Free Cash Flow | 33.58M | -50.08M | -3.62M | 10.96M | -42.29M | -65.39M |
| Operating Cash Flow | 38.63M | -40.57M | 9.49M | 20.77M | -32.75M | -59.62M |
| Investing Cash Flow | -3.27M | -5.94M | -12.25M | 37.62M | 23.34M | 60.29M |
| Financing Cash Flow | -23.70M | -11.71M | 71.93M | -63.31M | 2.31M | -46.93M |
Winshine Science Co., Ltd. Technical Analysis
Winshine Science Co., Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
51 Neutral | HK$45.31M | 17.27 | -1.08% | ― | -34.70% | -550.00% | |
49 Neutral | HK$196.07M | ― | -37.89% | ― | -59.42% | 75.90% | |
48 Neutral | HK$157.39M | ― | -19.89% | ― | 84.26% | 44.41% | |
46 Neutral | HK$56.00M | ― | -31.72% | ― | -8.50% | 4.11% | |
41 Neutral | HK$152.02M | ― | -36.17% | ― | -13.96% | 64.58% | |
38 Underperform | HK$28.60M | ― | ― | ― | -7.53% | -93.38% |
Winshine Science Co., Ltd. Corporate Events
Winshine Science Co., Ltd. announced a change in its company secretary and authorized representative roles, effective October 17, 2025. Ms. Yu Nga Yan has resigned from her position, and Ms. Chan Yuk Yee, a seasoned professional with extensive experience in corporate governance, has been appointed as her successor. The company expressed gratitude to Ms. Yu for her contributions and welcomed Ms. Chan to her new role. This change is expected to strengthen the company’s governance practices and ensure compliance with Hong Kong’s regulatory requirements.
Winshine Science Co., Ltd. has announced a proposed rights issue, offering seven rights shares for every existing share at a subscription price of HK$0.14 per rights share, aiming to raise approximately HK$182 million. The rights issue is fully underwritten, with substantial shareholder Ms. Wang and her corporation, Peak Access, providing irrevocable undertakings to subscribe to their entitlements, potentially strengthening the company’s financial position and market presence.
Winshine Science Co., Ltd. announced significant changes in its executive leadership and board committees. Mr. Weng Zudian resigned as Executive Director and CEO, with Ms. Wang Jingyu taking over as CEO while retaining her role as Chairlady of the Board. Additionally, Ms. Wang Yumei resigned as an Independent Non-executive Director, and Mr. Wu Jiwei was appointed to this role and joined the Audit, Remuneration, and Nomination Committees. These changes aim to ensure a smooth transition and potentially strengthen the company’s governance and strategic direction.
Winshine Science Co., Ltd., listed on the stock exchange under the code 209, has updated its board of directors. The company has appointed Ms. Wang Jingyu as the Chairlady and Chief Executive Officer, alongside other executive, non-executive, and independent non-executive directors. This update reflects the company’s commitment to strengthening its governance structure, potentially impacting its strategic direction and stakeholder confidence.
Winshine Science Co., Ltd. has announced several measures to address liquidity and financial challenges, following a disclaimer of opinion on its going concern status. The company completed a placing agreement to raise funds, which are being used to repay loans, settle fees, and support working capital. Additionally, the company is negotiating with bondholders and financial advisers to manage outstanding debts and is implementing cost-control measures in its toy production segment to improve financial stability.
Winshine Science Company Limited announced the resignation of Mr. Wong Danny F. as an Executive Director, effective 30 September 2025. Mr. Wong is stepping down to focus on other business engagements, and there are no disagreements with the Board regarding his departure. The Board expressed gratitude for his contributions, and the announcement is not expected to impact the company’s operations or stakeholder relations.
Winshine Science Co., Ltd., a company incorporated in Bermuda, has updated its board of directors. The board consists of executive directors including Ms. Wang Jingyu as Chairlady, Mr. Weng Zudian as CEO, and Mr. Yiu Chun Kong, along with non-executive director Mr. Lin Shaopeng and independent non-executive directors Ms. Wang Yumei, Ms. Wu Yan Yee, and Ms. Wong Tin Ying Jade. The announcement outlines the roles and functions of the directors, highlighting the composition of the board committees, which include the Audit, Remuneration, and Nomination Committees. This update is significant for stakeholders as it reflects the company’s governance structure and may impact its strategic direction.
Winshine Science Co., Ltd. has announced further details regarding the use of proceeds from Placing A and Placing B, which have been fully utilized for the group’s general working capital. Additionally, the company has clarified details about its New Share Option Scheme, including the number of options available for grant and a correction to the maximum number of new shares to be issued under the scheme. These updates aim to provide transparency and ensure stakeholders are informed about the company’s financial strategies and shareholder plans.
Winshine Science Co., Ltd. has successfully completed the placing of new shares under a general mandate, issuing approximately 30.95 million shares at HK$0.35 each, raising a net total of approximately HK$10.32 million. The proceeds will be allocated towards loan repayment, settlement of audit and professional fees, and general corporate purposes, including staff salaries. This strategic move alters the company’s shareholding structure, with public shareholders now holding a larger portion of shares, potentially impacting the company’s market positioning and stakeholder interests.
Winshine Science Co., Ltd. has entered into a Placing Agreement with Imagi Brokerage Limited to place 30,951,496 new shares at a price of HK$0.350 per share. This placement, representing 20% of the existing total issued shares, is expected to raise gross proceeds of HK$10,833,023.60, which will be used for loan repayment and general corporate purposes. The move is aimed at strengthening the company’s financial position and operational capabilities.
Winshine Science Company Limited, listed on the Hong Kong Stock Exchange, announced significant changes in its shareholder structure and executive leadership. The company saw a change in its substantial shareholder as Mr. Li, through Hurray Talent, sold 24.16% of the company’s shares to Peak Access, owned by Ms. Wang. This transaction led to Ms. Wang becoming a substantial shareholder. Concurrently, Mr. Li and Mr. Jiang resigned from their roles as Executive Directors, with Mr. Jiang also stepping down as Chairman of the Board. Ms. Wang has been appointed as the new Executive Director and Chairlady of the Board, while Mr. Lin and Ms. Wong have taken new roles within the Nomination Committee. These changes are aimed at ensuring a smooth transition and maintaining the company’s strategic direction.
Winshine Science Co., Ltd. reported its interim financial results for the six months ending June 30, 2025, revealing a significant financial downturn. The company experienced a gross loss of HK$10,035,000 compared to a profit in the previous year, with overall losses before tax amounting to HK$38,349,000. This reflects a challenging period for the company, impacting its financial standing and potentially affecting stakeholder confidence.
Winshine Science Co., Ltd. has announced several key appointments to its board, including the appointment of Mr. Yiu Chun Kong as an executive director and Ms. Wu Yan Yee and Ms. Wong Tin Ying Jade as independent non-executive directors, effective August 22, 2025. These appointments are part of the company’s efforts to comply with various listing rules and enhance its governance structure. The new directors bring extensive experience in finance, accounting, and asset management, which is expected to strengthen the company’s strategic direction and oversight.
Winshine Science Co., Ltd. has released a supplemental announcement to its 2024 Annual Report, detailing the use of proceeds from two share placements conducted in 2024. The proceeds from Placing A and Placing B, amounting to HK$6.5 million and HK$4.3 million respectively, were allocated as general working capital to cover audit fees, listing fees, and administrative expenses. This strategic allocation supports the company’s operational needs and financial stability.
Winshine Science Co., Ltd. has issued a profit warning, expecting a loss of approximately HKD38 million for the first half of 2025, compared to a HKD27 million loss in the same period last year. The increased loss is attributed to higher tariffs imposed by the United States on China, leading to decreased product orders and gross profits, as well as rising minimum wage and social insurance costs in China.
Winshine Science Co., Ltd. has announced an upcoming board meeting scheduled for August 29, 2025, where the board will approve the interim results for the first half of the year and discuss the potential recommendation of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and strategic decisions, potentially impacting its market positioning and shareholder value.
Winshine Science Co., Ltd. announced the resignation of Mr. Kwok Kim Hung Eddie as an independent non-executive director, effective August 8, 2025. This resignation has resulted in non-compliance with several Hong Kong Stock Exchange Listing Rules regarding the composition of the board, audit, and nomination committees. The company is actively seeking suitable candidates to fill the vacancies and aims to comply with the listing requirements within three months.
Winshine Science Co., Ltd. has announced an update to its board of directors, highlighting the roles and functions of its executive, non-executive, and independent non-executive directors. This update may impact the company’s governance structure and strategic direction, potentially affecting its market positioning and stakeholder relations.
Winshine Science Company Limited has announced the appointment of Mr. Wong Danny F. as an executive director, effective from July 29, 2025. Mr. Wong brings over 25 years of experience in the finance industry, having held significant positions in various financial institutions, and is expected to contribute to the company’s strategic direction and growth. His appointment is seen as a strategic move to enhance the company’s leadership team, potentially impacting its operations and market positioning positively.
Winshine Science Company Limited has announced an update to its board of directors, highlighting the roles and functions of each member. The board comprises executive, non-executive, and independent non-executive directors, with specific members assigned to various board committees such as audit, remuneration, and nomination. This update reflects the company’s ongoing commitment to transparency and structured governance, potentially impacting its strategic direction and stakeholder confidence.